Why is Senores Pharma. falling/rising?

As of 18-Sep, Senores Pharmaceuticals Ltd is experiencing a price increase, currently at 715.90, reflecting a change of 25.55 or 3.7% upward. The stock has shown strong performance today, outperforming its sector by 2.65% and has been gaining for the last two days, with a total return of 4.62% during this period. It is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite these positive indicators, there is a noted decline in investor participation, with delivery volume falling by 26.7% against the 5-day average. The company boasts a low debt-to-equity ratio and impressive long-term growth metrics, including a significant increase in net sales and operating profit. However, the stock's valuation appears expensive, with a price-to-book value of 4.2, and institutional investors have reduced their stake slightly.
In the broader market context, Senores Pharmaceuticals has delivered a 0.82% return over the past week, which is lower than the Sensex's 1.80% increase, indicating that while the stock is rising, it is not keeping pace with the overall market. Over the past month, the stock has gained 2.56%, slightly outperforming the Sensex's 2.14%. The company’s recent positive earnings results and growth in sales have contributed to its upward price movement, but the decrease in institutional investor participation may signal caution among more knowledgeable market players. Overall, while the stock is currently rising, it faces challenges that could impact its future performance.